Lumiera ends fiscal year strong with sales in November 2021 up 59% compared to November 2020

·4 min read

MONTREAL, Dec. 2, 2021 /CNW Telbec/ - Lumiera Health Inc. (TSXV: NHP) (the "Company" or "Lumiera "), a company specializing in the development and commercialization of natural health products, is pleased to provide an update to announce that the new corporate strategy and plans that were put in place Q1-Q3 2021 have been successful. Lumiera's fiscal Q4 was a record quarter with sales +30% vs Q4 2020, highlighted by November which was a record sale month, +59.3% over November 2020.

Lumiera Health Inc. logo (CNW Group/Lumiera Health Inc.)
Lumiera Health Inc. logo (CNW Group/Lumiera Health Inc.)

The increase in the Company's sales and the accelerated quarter over quarter growth was driven by the success of expanded distribution, new digital and retail marketing campaigns, and the successful performance of a new sales and in-store training team put in place earlier in the year.

"2021 has been a foundation building year; I am really proud of the team - we developed new strategies and plans, we pulled the business apart, eliminated waste and refocused the team and resources behind those strategies to drive growth of our priority brands and products in both online and retail channels." says Carlos Ponce, CEO of Lumiera Health. "After a challenging front half of the year we are happy to finish the year with sales of +10% and to see that the positive initial results in our Q4 sales is outstanding. We are looking forward to keep building momentum for a great 2022 and beyond."

Management will continue executing its plan for growth and expects to see the upward sales trends continue for the foreseeable future.

Audited financial statements will be released on or before March 31, 2022.

About Lumiera Health

Lumiera specializes in the development and commercialization of consumer products for the natural health industry. The Company sells herbal tonics and natural supplements through its Holizen Laboratories division, with a diverse portfolio including a line of innovative sleep aids. The Company is also developing and commercializing a unique range of products acting on the endocannabinoid system and offering novel solutions for the treatment of acute and chronic pain. A pioneer in the natural health innovation space, the Lumiera brand is rooted in the core values of science, nature and compassion. Our goal is to make people's lives better by developing natural health and wellness products that are effective, safe and trustworthy.

For more information visit: www.lumiera.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions indicate such "forward-looking information" as they relate to Lumiera. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Lumiera' current views and intentions with respect to future events, and current information available to Lumiera, and are subject to certain risks, uncertainties and assumptions. Such risks and uncertainties include, among others, the risk factors included in Lumiera' annual management's discussion and analysis for the year ended November 30, 2020, which is available under the issuer's SEDAR profile at www.sedar.com. Material factors or assumptions were applied in providing forward-looking information. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Lumiera in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Lumiera does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Lumiera undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

SOURCE Lumiera Health Inc.

Cision
Cision

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/02/c7294.html

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting